Loading…
Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health. Its Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. Its Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company serves federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. Addus HomeCare Corporation was founded in 1979 and is based in Frisco, Texas.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1.4B | $157M | $96M | $104M | 8.8% | 23.2% | 30.3% |
| 2024 | $1.2B | $121M | $74M | $110M | 7.6% | 9.1% | 17.7% |
| 2023 | $1.1B | $107M | $63M | $103M | 8.8% | 11.3% | 35.8% |
| 2022 | $951M | $83M | $46M | $97M | 7.3% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 951.12 | 1,058.65 | 1,154.60 | 1,422.53 |
| Operating Revenue | - | 951.12 | 1,058.65 | 1,154.60 | 1,422.53 |
| Cost Of Revenue | - | 651.38 | 718.78 | 779.58 | 960.66 |
| Gross Profit | - | 299.74 | 339.88 | 375.02 | 461.87 |
| Operating Expense | - | 231 | 248.92 | 272.33 | 323.26 |
| Selling General And Administration | - | 216.94 | 234.79 | 258.80 | 306.85 |
| Total Expenses | - | 882.38 | 967.70 | 1,051.91 | 1,283.92 |
| Operating Income | - | 68.74 | 90.96 | 102.69 | 138.62 |
| Total Operating Income As Reported | - | 68.74 | 90.96 | 102.69 | 138.62 |
| EBITDA | - | 83.14 | 106.56 | 120.62 | 157.47 |
| Normalized EBITDA | - | 83.14 | 106.56 | 120.62 | 157.47 |
| EBIT | - | 69.08 | 92.43 | 107.08 | 141.06 |
| Interest Income | - | 0.34 | 1.48 | 4.39 | 2.44 |
| Interest Expense | - | 8.91 | 11.11 | 7.73 | 13.61 |
| Net Interest Income | - | -8.57 | -9.63 | -3.34 | -11.17 |
| Interest Income Non Operating | - | 0.34 | 1.48 | 4.39 | 2.44 |
| Interest Expense Non Operating | - | 8.91 | 11.11 | 7.73 | 13.61 |
| Net Non Operating Interest Income Expense | - | -8.57 | -9.63 | -3.34 | -11.17 |
| Pretax Income | - | 60.17 | 81.33 | 99.35 | 127.44 |
| Tax Provision | - | 14.15 | 18.81 | 25.76 | 31.54 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | 46.02 | 62.52 | 73.60 | 95.91 |
| Net Income From Continuing And Discontinued Operation | - | 46.02 | 62.52 | 73.60 | 95.91 |
| Net Income From Continuing Operation Net Minority Interest | - | 46.02 | 62.52 | 73.60 | 95.91 |
| Net Income | - | 46.02 | 62.52 | 73.60 | 95.91 |
| Net Income Common Stockholders | - | 46.02 | 62.52 | 73.60 | 95.91 |
| Net Income Including Noncontrolling Interests | - | 46.02 | 62.52 | 73.60 | 95.91 |
| Normalized Income | - | 46.02 | 62.52 | 73.60 | 95.91 |
| Diluted NI Availto Com Stockholders | - | 46.02 | 62.52 | 73.60 | 95.91 |
| Basic Average Shares | - | 16.13 | 16.23 | 18.15 | 18.52 |
| Diluted Average Shares | - | 16.18 | 16.31 | 18.15 | 18.52 |
| Reconciled Depreciation | - | 14.06 | 14.13 | 13.53 | 16.41 |
| Reconciled Cost Of Revenue | - | 651.38 | 718.78 | 779.58 | 960.66 |
| Net Income Discontinuous Operations | 0 | - | - | - | - |
| Depreciation Amortization Depletion Income Statement | - | 14.06 | 14.13 | 13.53 | 16.41 |
| Depreciation And Amortization In Income Statement | - | 14.06 | 14.13 | 13.53 | 16.41 |
| General And Administrative Expense | - | 216.94 | 234.79 | 258.80 | 306.85 |
| Other Gand A | - | 216.94 | 234.79 | 258.80 | 306.85 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Addus HomeCare Corporationthis co. | ADUS | $1.7B | 17.46 | 1.54 | 8.8% | 11.20 |
| Biohaven Ltd. | BHVN | $1.7B | -2.32 | 32.96 | -1418.8% | -2.41 |
| Agios Pharmaceuticals, Inc. | AGIO | $1.7B | -4.15 | 1.44 | -34.6% | -3.56 |
| Sionna Therapeutics, Inc. | SION | $1.7B | -22.66 | 5.56 | -24.5% | -18.75 |
| Taysha Gene Therapies, Inc. | TSHA | $1.7B |
| - |
| - |
| - |
| - |
| - |
| - |
| -15.53 |
| 6.85 |
| -44.1% |
| -13.39 |
| Novavax, Inc. | NVAX | $1.7B | 3.81 | -13.12 | -344.7% | 3.42 |
| GeneDx Holdings Corp. | WGS | $1.7B | -79.47 | 5.42 | -6.8% | 138.20 |
| Palvella Therapeutics, Inc. | PVLA | $1.6B | -39.48 | 58.85 | -149.1% | -44.28 |
| Innoviva, Inc. | INVA | $1.6B | 6.03 | 1.39 | 23.1% | 3.66 |
| Peer Median | - | -9.84 | 5.49 | -39.4% | -2.99 | |